Alector Stock
Therapeutics for neurodegenerative disorders
Sign up today and learn more about Alector Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Alector Stock
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.
Funding History
October 2013 | $0 |
---|---|
March 2014 | $0 |
September 2015 | $32.0M |
January 2016 | $29.5M |
July 2018 | $133M |
Management
Founder, President & Chief Executive Officer
Arnon Rosenthal
Founder & Chairman of the Board
Tillman Gerngross
Founder & SAB Member
Asa Abeliovich
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase